Myasthenia gravis is an autoimmune disease in which the acetylcholine receptor (AChR) at the neuromuscular junction is a major auto-antigen.' Anti-AChR antibodies are usually present in the sera of myasthenic patients2 and this provides an aid to diagnosis of the disease although the correlation of anti-(human AChR) antibody titres with disease state is generally poor.3~We recently examined" the relative merits of human and rat AChR as antigen in the routine radioimmunoassay of anti-AChR antibodies in the sera of patients with myasthenia gravis. The anti-(rat AChR) antibody titres were generally found to be much lower than corresponding anti-(human AChR) titres and, like the latter, showed no obvious correlation with severity of symptoms in the myasthenic patients. Although the ratio of anti-(rat AChR) antibody titre: anti-(human AChR) antibody titre varied widely from patient to patient, limited numbers of serial serum assays on individual patients suggested that the ratio might be constant for and characteristic of a given patient. In view of the possible implications of these observations for the mechanisms of pathogenesis of myasthenia gravis, we have examined both anti-(rat AChR) and anti-(human AChR) antibody titres in the sera of ten myas-thenic patients monitored over a span of several months which included periods of plasmaexchange combined with immunosuppressive therapy.
Patients and methods
Ten patients with myasthenia gravis were studied. There were 6 females and 4 males, whose ages ranged from 26 to 75 years with a mean of 49 years. Nine patients had the generalized form of the disease whereas in one (Case 6) the eye muscles only were clinically affected. Myasthenia had been present from three to 18 years with a mean duration of seven years. Nine patients had had a thymectomy previously.
During the period of study all patients underwent at least one course of plasma exchanges. Each course ranged from one to eight individual exchanges of four litres of plasma. Replacement fluid was plasma protein fraction.
All patients were on anticholinesterase therapy throughout the period of study and were placed on prednisolone (100 mg daily) and azathioprine (150 mg daily) at the commencement of plasma exchange. The Anti-(humran AChR) antibodies and anti-(rat AChR) antibodies in the sera of myasthenic patients were assayed by using 125I-a-bungarotoxin-labelled AChR in a modification of the assay described by Lindstrom.7 AChR extract containing approximately 0 5 nM specific toxin-binding sites was incubated for 90 min at +200C with a fivefold excess of 1251-a-bungarotoxin in phosphate-buffered Triton X-100 (as above). The resulting 125I-a-bungarotoxin-AChR solution (100 ul) was incubated with myasthenic serum or a sample (5 i'1), seriallydiluted (with normal human serum), for 16 h at +4°C. The labelled AChR-antibody complex was precipitated by addition of goat anti-(human IgG) antiserum and allowed to stand for 15 h at +4°C. The precipitate was separated by centrifugation at 3000 g for 10 min and the pellet was washed twice with 0 01 M-potassium phosphate buffer, pH 7-4, containing 0-15 M-NaCl, 1% v/v Triton X-100, 1o% "/, bovine serum albumin and 0-02% NaN3 and counted in a y-counter. Non-specific counts were subtracted as described above.
All assays were performed in duplicate and maximal precipitation of anti-(AChR) antibodies was ensured by the use of serially-diluted serum sample controls. It is of interest that the constant ratio of anti-(e.j. rat AChR): anti-(human AChR) antibody titres is apparently unaffected by the combined plasma-exchange and immunosuppressive treatments experienced by all the patients monitored, despite the obvious fall in both titres during the period of treatment and the clear clinical improvement following the treatment. 8 Moreover, titre ratios characteristic of the patient were also obtained from serum samples taken at intervals of up to several months before (Cases 1, 2, 3, 5) and after (Cases 2, 4, 9) plasma-exchange.
It has been suggested13 that plasma-exchange combined with anti-metabolite administration could lead to a semi-selective cytotoxic action in lymphocytes proliferating in response to removal of anti-AChR antibodies from the circulation, and the particular clinical effectiveness of an extensive series of plasma-exchanges coupled with azathioprine therapy would support this mechanism.5 It has been further suggested, following studies on experimental myasthenia gravis in rabbits,'4 that azathioprine can selectively suppress certain anti-AChR antibody subpopulations. Our present results, while containing only a limited number of serum samples taken prior to azathioprine treatment, show no evidence of such selective suppression.
We also determined the anti-(j. rat AChR) antibody titre in selected serum samples from all ten myasthenic patients and the ratios of anti-(j. rat AChR): anti-(e.j. rat AChR) antibody titre are shown in the Table. The anti-(j. rat AChR) antibody titres were lower than the corresponding anti-(e.j. rat AChR) titres in all but two out of 28 serum samples assayed and could not be detected at all in samples taken from three patients (Cases 1, 2, 6). Weinberg and Hall'2 similarly compared antiAChR antibody titres in 10 samples of myasthenic sera using junctional and extrajunctional rat AChR and found ratios of anti-(j. rat AChR): anti-(e.j. rat AChR) antibody titres varying from 06 to 1-0. Our results clearly show a greater spread of ratios than those reported by Weinberg and Hall but agree with those of the latter authors in being generally less than 1-0 (table). Weinberg and Hall suggest that myasthenic serum, with its apparent content of anti-AChR antibodies specific for extrajunctional receptors. might find a use in detection and purification of such receptors. Our observation that some myasthenic sera (Cases 1, 2, 6) contain anti-(rat AChR) receptors only of this type strengthens the feasibility of this approach.
Although the ratios of anti-(j. rat AChR): anti-(e.j. rat AChR) antibody titres are not quite as consistent as the anti-(rat AChR): anti-(human AChR) titre ratios previously discussed they do appear to be largely characteristic of the individual patient and so provide further support for the concept of a heterogeneous pattern of anti-AChR antibodies in myasthenic sera that is patient-specific.
The relative abilities of different myasthenic sera to precipitate a-bungarotoxin-labelled human AChR were assessed. The amount of AChR precipitated from a given antigen solution by excess serum was found to vary with the serum sample. Samples from Case 3 consistently precipitated more AChR than did other sera which were accordingly routinely compared with the former sera ( The apparent constancy of anti-AChR antibody patterns of a given patient over a period of time and throughout a range of treatments may well have relevance to the progress of myastl-enia gravis in any individual. The course of the disease in different patients and the responses of the latter to therapy are known to vary considerably and it may be that clues to the basis of these differences will be found in continued study of the patterns of anti-AChR antibody sub-populations and in their correlation with the case histories of myasthenic patients. 
